Nintedanib in NSCLC: Evidence to date and place in therapy

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 3, 2016, Pages 188-197

  Bronte, Giuseppe ^a   Passiglia, Francesco ^a   Galvano, Antonio ^a   Barraco, Nadia ^a   Listì, Angela ^a   Castiglia, Marta ^a   Rizzo, Sergio ^a   Fiorentino, Eugenio ^a   Bazan, Viviana ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

angiogenesis; FGFR; nintedanib; NSCLC; PDGFR; targeted therapy; VEGFR

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN 4; NINTEDANIB;

ALGORITHM; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; DRUG TOLERABILITY; HUMAN; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84968919942     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834016630976     Document Type: Review

References (47)

1. Besse B., Johnson M., Janne P., Garassino M., Eberhardt W., Peters S., et al. (2015) Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Ann Oncol 26 (Suppl. 6): abstract 16LBA.
2. Borghaei H., Paz-Ares L., Horn L., Spigel D., Steins M., Ready N., et al. (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer., N Engl J Med 373: 1627-1639.
3. Brahmer J., Reckamp K., Baas P., Crinò L., Eberhardt W., Poddubskaya E., et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer., N Engl J Med 373: 123-135.
4. Bronte G., Passiglia F., Galvano A., Russo A., (2015) Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?, Expert Opin Biol Ther 3 2015. [Epub ahead of print].
5. Bronte G., Rizzo S., La Paglia L., Adamo V., Siragusa S., Ficorella C., et al. (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma., Cancer Treat Rev 36 (Suppl. 3): S21-S29.
6. Bronte G., Rolfo C., Giovannetti E., Cicero G., Pauwels P., Passiglia F., et al. (2014) Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects., Crit Rev Oncol Hematol 89: 300-313.
7. Daga H., Takeda K., Okada H., Miyazaki M., Ueda S., Kaneda H., et al. (2013) Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): a phase I study. J Clin Oncol 31 (Suppl.): abstract 8056.
8. De Boer R., Arrieta Ó., Yang C., Gottfried M., Chan V., Raats J., et al. (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial., J Clin Oncol 29: 1067-1074.
9. Doebele R., Conkling P., Traynor A., Otterson G., Zhao Y., Wind S., et al. (2012) A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer., Ann Oncol 23: 2094-2102.
10. Ellis P., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N., (2010) Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients., Clin Cancer Res 16: 2881-2889.
11. Folkman J., (1990) What is the evidence that tumors are angiogenesis dependent?, J Natl Cancer Inst 82: 4-6.
12. Garon E., Ciuleanu T., Arrieta O., Prabhash K., Syrigos K., Goksel T., et al. (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial., Lancet 384: 665-673.
13. Garon E., Rizvi N., Hui R., Leighl N., Balmanoukian A., Eder J., et al. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer., N Engl J Med 372: 2018-2028.
14. Gettinger S., Horn L., Gandhi L., Spigel D., Antonia S., Rizvi N., et al. (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer., J Clin Oncol 33: 2004-2012.
15. Hanna N., Kaiser R., Sullivan R., Aren O., Ahn M., Tiangco B., et al. (2013) LUME-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 31 (Suppl.): abstract 8034.
16. Heigener D., Reck M., Mellemgaard A., Orlov S., Krzakowski M., von Pawel J., et al. (2015) Efficacy of nintedanib plus docetaxel after bevacizumab, pemetrexed or taxane therapy. Presented at 16th World Conference on Lung Cancer (WCLC 2015), mini-oral 17.07. http://library.iaslc.org/search-speaker?search-speaker=32414
17. Herbst R., Sun Y., Eberhardt W., Germonpré P., Saijo N., Zhou C., et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial., Lancet Oncol 11: 619-626.
18. Hilberg F., Roth G., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res 68: 4774-4782.
19. Huang R., Kuay K., Tan T., Asad M., Tang H., Ng A., et al. (2015) Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)., Oncotarget 6: 22098-22113.
20. Jackson A., Zhou B., Kim W., (2010) HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer., Expert Opin Ther Targets 14: 1047-1057.
21. Kutluk Cenik B., Ostapoff K., Gerber D., Brekken R., (2013) BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer., Mol Cancer Ther 12: 992-1001.
22. Li N., Yang L., Ou W., Zhang L., Zhang S., Wang S., (2014) Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer., PLoS One 9: e102777.
23. Lopez-Chavez A., Young T., Fages S., Leon L., Schiller J., Dowlati A., et al. (2012) Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis., J Thorac Oncol 7: 1707-1712.
24. Mross K., Stefanic M., Gmehling D., Frost A., Baas F., Unger C., et al. (2010) Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors., Clin Cancer Res 16: 311-319.
25. Novello S., Kaiser R., Mellemgaard A., Douillard J., Orlov S., Krzakowski M., et al. (2015) Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer., Eur J Cancer 51: 317-326.
26. Okamoto I., Miyazaki M., Takeda M., Terashima M., Azuma K., Hayashi H., et al. (2015) Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer., J Thorac Oncol 10: 346-352.
27. Onimaru M., Yonemitsu Y., (2011) Angiogenic and lymphangiogenic cascades in the tumor microenvironment., Front Biosci (Schol Ed) 3: 216-225.
28. Osarogiagbon R., Cappuzzo F., Ciuleanu T., Leon L., Klughammer B., (2015) Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials., Transl Lung Cancer Res 4: 465-474.
29. Pallis A., Syrigos K., (2013) Targeting tumor neovasculature in non-small-cell lung cancer., Crit Rev Oncol Hematol 86: 130-142.
30. Passiglia F., Bronte G., Castiglia M., Listì A., Calò V., Toia F., et al. (2015a) Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?, Expert Opin Biol Ther 15: 1553-1566.
31. Passiglia F., Bronte G., Rizzo S., Galvano A., Sortino G., Musso E., et al. (2015b) PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Presented at 16th World Conference on Lung Cancer (WCLC 2015), mini-oral 31.01. http://library.iaslc.org/search-speaker?search-speaker=35078
32. Paz-Ares L., Biesma B., Heigener D., von Pawel J., Eisen T., Bennouna J., et al. (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer., J Clin Oncol 30: 3084-3092.
33. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J., Bidoli P., et al. (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer., J Clin Oncol 31: 2895-2902.
34. Peters S., Adjei A., Gridelli C., Reck M., Kerr K., Felip E., et al. (2012) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol 23 (Suppl. 7): vii56-vii64.
35. Piperdi B., Merla A., Perez-Soler R., (2014) Targeting angiogenesis in squamous non-small cell lung cancer., Drugs 74: 403-413.
36. Reck M., Kaiser R., Mellemgaard A., Douillard J., Orlov S., Krzakowski M., et al. (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial., Lancet Oncol 15: 143-155.
37. Reck M., Mellemgaard A., von Pawel J., Gottfried M., Bondarenko I., Cheng Y., et al. (2015) Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel., Lung Cancer 90: 267-273.
38. Rolfo C., Passiglia F., Castiglia M., Raez L., Germonpre P., Gil-Bazo I., et al. (2014) ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it., Transl Lung Cancer Res, 3 (4),pp. 250-61.
39. Rolfo C., Raez L., Bronte G., Santos E., Papadimitriou K., Buffoni L., et al. (2013) BIBF 1120/ nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer., Expert Opin Investig Drugs 22: 1081-1088.
40. Roth G., Binder R., Colbatzky F., Dallinger C., Schlenker-Herceg R., Hilberg F., et al. (2015) Nintedanib: from discovery to the clinic., J Med Chem 58: 1053-1063.
41. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J., Thomas M., et al. (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer., J Clin Oncol 28: 1835-1842.
42. Scagliotti G., Krzakowski M., Szczesna A., Strausz J., Makhson A., Reck M., et al. (2012a) Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial., J Clin Oncol 30: 2070-2078.
43. Scagliotti G., Vynnychenko I., Park K., Ichinose Y., Kubota K., Blackhall F., et al. (2012b) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1., J Clin Oncol 30: 2829-2836.
44. Shepherd F., Rodrigues Pereira J., Ciuleanu T., Tan E., Hirsh V., Thongprasert S., et al. (2005) Erlotinib in previously treated non-small-cell lung cancer., N Engl J Med 353: 123-132.
45. Vale C., Burdett S., Fisher D., Navani N., Parmar M., Copas A., et al. (2015) Should tyrosine kinase inhibitors be considered for advanced non-small-cell lung cancer patients with wild type EGFR? Two systematic reviews and meta-analyses of randomized trials., Clin Lung Cancer 16: 173-182.
46. Villaruz L., Socinski M., (2015) The role of anti-angiogenesis in non-small-cell lung cancer: an update., Curr Oncol Rep 17: 26.
47. Zhao N., Zhang X., Yan H., Yang J., Wu Y., (2014) Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials., Lung Cancer 85: 66-73.